Coya Therapeutics (COYA) announced that the FDA has accepted the company’s investigational new drug application for COYA 302 for the treatment of frontotemporal dementia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target
- Coya announces Health Canada acceptance of COYA 302 clinical trial application
- Coya Therapeutics Receives $4.2M Milestone Payment
- Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects
- Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302